Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Organization

Department of Haematology, Guy’s and St Thomas’ NHS Foundation Trust

1 abstract

Abstract
Phase 3 randomized double-blind study evaluating selinexor, an XPO1 inhibitor, plus ruxolitinib in JAKi-naïve myelofibrosis.
Org: VCU Massey Comprehensive Cancer Center, Department of Medicine, Leukemia Service, Memorial Sloan Kettering Cancer Center, Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Hospital, Department of Haematology, Guy’s and St Thomas’ NHS Foundation Trust,